CONTENTS
· Invitation
· Scientific Agenda
· Call For Abstracts
· Continuing
  Medical Education
· Target Audience
· Objectives
· Registration
· Organizer

Melissa Alsina, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Dean F. Bajorin, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Harold J. Burstein, MD, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts

Mary E. Cianfrocca, DO
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Jorge Cortes, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Robert Dreicer, MD, FACP
Cleveland Clinic
Taussig Cancer Center
Cleveland, Ohio

Robert A. Figlin, MD, FACP
City of Hope Comprehensive Cancer Center
Duarte, California

Keith T. Flaherty, MD
University of Pennsylvania
Abramson Cancer Center
Philadelphia, Pennsylvania

Generosa Grana, MD
Cooper University Hospital
Voorhees, New Jersey

Robert I. Haddad, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

Frederick Hagemeister, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Daniel G. Haller, MD
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania

Nasser H. Hanna, MD
Indiana University
Indianapolis, Indiana

J. Randolph Hecht, MD
UCLA Med-Hematology
& Oncology
Los Angeles, California

Sandra J. Horning, MD
Stanford University
Medical Center
Stanford, California

David H. Ilson, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York

Michael J. Kaplan, MD
Stanford University School
of Medicine
Stanford, California

Neil E. Kay, MD
Mayo Clinic
Rochester, Minnesota

Michael J. Keating, MD, BS
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Karen L. Kelly, MD
The University of Kansas Medical Center
Kansas City, Kansas

Merrill S. Kies, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Corey J. Langer, MD, FACP
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Sagar Lonial, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia

Thomas J. Lynch, MD
Massachusetts General Hospital
Boston, Massachusetts

Owen A. O’Conner, MD, PhD
Columbia University
Herbert Irving Comprehensive Cancer Center
New York, New York

Ruth M. O’Regan, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia

S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota

Antoni Ribas, MD
University of California School of Medicine
Los Angeles, California

Hope S. Rugo, MD
University of California
San Francisco Medical Center
San Francisco, California

Christy A. Russell, MD
University of Southern California
Los Angeles, California

Mark A. Socinski, MD
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Mark S. Soloway, MD
Miller School of Medicine
University of Miami
Miami, Florida

Anne S. Tsao, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Eric Vallieres, MD, FRCSC
Swedish Cancer Institute
Seattle, Washington

Ravi Vij, MD
Washington University School of Medicine
St. Louis, Missouri

Nicholas J. Vogelzang, MD
Nevada Cancer Institute
Las Vegas, Nevada

Julie Vose, MD
University of Nebraska Medical Center
Omaha, Nebraska

Jeff Weber, MD, PhD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Howard L. West, MD
Swedish Cancer Institute
Seattle, Washington

7:00 am
Registration & Breakfast

8:00 am
Welcome and Introduction

8:15 am
Lung Cancer

• Biomarkers and proteomics in lung cancer
  
• Multimodal management strategies of advanced NSCLC
  
• Emerging novel agents for NSCLC

9:30 am
Genitourinary Cancers

• Prostate cancer
  
• Renal cell cancer
  
• Bladder cancer

10:10 am
Break

10:30 am
Breast Cancer

• Advances in diagnostics and prognostics
  
• Endocrine therapy and resistance
  
• Chemotherapy and targeted therapies
  
• Novel therapies targeting tumor vasculature

11:10 pm
Gastrointestinal Cancers

• Gastric and esophageal cancers
• Pancreatic cancer
  
• Colorectal cancer
  
• Hepatocellular carcinoma

11:50 am
Lunch

12:45 pm
Other Tumor Types

• Melanoma and skin cancers
  
• Head and neck cancers

2:00 pm
Break

2:15 pm
Hematologic Malignancies

• Leukemias, myelodysplasia, and transplantation
  
• Lymphomas
  
• Myelomas and plasma cell disorders

4:00 pm
Adjourn

** This is a draft agenda. Final topics to be selected based on abstracts released during the 44th ASCO^® Annual Meeting

ACCME (Physicians)

Imedex^®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 6.0 of AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACPE (Pharmacists)

Imedex, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This course (Universal Program Number 408-000-08-001-L01-P) has been approved for a maximum of 6.0 contact hours (0.6 CEUs).

There is a fee to participate in this activity. No partial credit will be awarded. Participants must complete an evaluation form and credit request form at the conclusion of the activity to receive a credit statement. Statements of credit will be issued via USPS within six weeks of the conclusion of the program.

This educational activity is specifically designed for medical and radiation oncologists, gastroenterologists, colorectal surgeons and other healthcare professionals (gastroenterology and oncology nurses) in active clinical practice who wish to review and update their knowledge and management of colorectal cancer.

After successfully completing this educational activity, participants should be able to:

• Discuss the most clinically relevant data presented at The 44th ASCO® Annual Meeting
• Describe the various treatment regimens or therapies for multiple tumor types
  
• Evaluate the new and emerging management strategies for the treatment of patients with multiple tumor types, focusing on the benefits and limitations of each
  
• Integrate the emerging data presented at The 44th ASCO® Annual Meeting into their clinical practice

PHARMACY EDUCATIONAL OBJECTIVES
After successful completion of this activity, participants should be able to:

• Discuss the most clinically relevant data presented at The 44th ASCO® Annual Meeting
  
• Describe the various treatment regimens or therapies for multiple tumor types
  
• Evaluate the new and emerging management strategies for the treatment of patients with multiple tumor types, focusing on the benefits and limitations of each
  
• Integrate the emerging data presented at The 44th ASCO® Annual Meeting into their clinical practice
  
• Incorporate knowledge of evolving treatment strategies into patient counseling practices to improve disease and supportive care management

Click here to register for this program

REGISTRATION FEES: $75.00

PHARMACEUTICAL NON-SUPPORTERS FEES: $175.00

To Register: You may register online at www.imedex.com or by calling +1 (678) 242 0906. Registration confirmations will be issued before the meeting.

Payment: To pre-register, registration and payment must be received no later than 5 business days before the conference start date. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our Website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check Checks should be payable to Imedex. Include the full name of the attendee and the name of the conference: A043 – ASCO HL Series. An attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than 5 business days before the conference start date. The amount of registration fees remitted, minus a $25 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 5 business days before the conference start date.

Imedex does not accept responsibility for covering travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event content is subject to change without notice.
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

          4325 Alexander Drive
          Alpharetta, GA 30022-3740 USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com